Diversified LLC Purchases 98 Shares of Merck & Co., Inc. (NYSE:MRK)

Diversified LLC increased its stake in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 1.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,362 shares of the company’s stock after purchasing an additional 98 shares during the quarter. Diversified LLC’s holdings in Merck & Co., Inc. were worth $839,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vermillion & White Wealth Management Group LLC bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $27,000. Bare Financial Services Inc bought a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $28,000. Burkett Financial Services LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $28,000. Rakuten Securities Inc. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $30,000. Finally, RIA Advisory Group LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $30,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $126.08 on Wednesday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25. The stock has a 50 day simple moving average of $128.99 and a 200 day simple moving average of $125.39. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $134.63. The firm has a market capitalization of $319.34 billion, a PE ratio of 140.09, a P/E/G ratio of 2.43 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.13. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.21 billion. During the same period in the previous year, the firm earned $1.40 EPS. Merck & Co., Inc.’s quarterly revenue was up 8.9% compared to the same quarter last year. Sell-side analysts predict that Merck & Co., Inc. will post 8.62 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, July 8th. Shareholders of record on Monday, June 17th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 2.44%. The ex-dividend date of this dividend was Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 342.22%.

Analyst Upgrades and Downgrades

MRK has been the topic of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 target price on shares of Merck & Co., Inc. in a research note on Tuesday, June 18th. Berenberg Bank upped their price target on Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Truist Financial upped their price target on Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Wells Fargo & Company upped their price target on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 27th. Finally, Argus raised Merck & Co., Inc. to a “strong-buy” rating in a research note on Wednesday, June 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $133.00.

Check Out Our Latest Report on MRK

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.